Monday, November 24th 2025
​
ProtonDx joins PACE-AMR programme to develop Dragonfly to tackle UTIs​
High-impact antimicrobial resistance innovations programme chooses Dragonfly to be adapted as a new, rapid test for the effective management of urinary tract infections (UTIs).
London UK, November 24th, 2025 - ​​We are immensely proud to be selected for the PACE-AMR programme, a vital initiative dedicated to accelerating high-impact antimicrobial resistance (AMR) innovations.
​
This partnership enables us to adapt Dragonfly™, our existing portable diagnostics platform, to develop a new, rapid test for the effective management of urinary tract infections (UTIs).
Having already been validated for respiratory viruses, malaria and mpox, the sample-to-result workflow is ready to be adapted for urine-based UTI testing to report results at clinically relevant levels within 30 minutes.
Read more about how we are working to improve patient outcomes and antimicrobial stewardship on the PACE-AMR website.
​​​